The production of a peptide bond between two amino acids is referred to as peptide synthesis. The carboxyl group of the entering amino acid is typically coupled to the N-terminus of the developing peptide chain during peptide synthesis. Even in high-throughput biological research and product and medication development, peptide synthesis is a prevalent strategy.
The rising prevalence of metabolic illnesses such as diabetes is likely to fuel the expansion of the peptide synthesis market. For example, the journal Diabetes Research and Clinical Practice released an article titled 'Global and regional diabetes prevalence estimates for 2019 with forecasts for 2030 and 2045: According to the International Diabetes Federation Diabetes Atlas, 9th edition, published in September 2019, 463 million people worldwide are anticipated to have diabetes in 2019, with the number expected to rise to 578 million by 2030 and 700 million by 2045.
However, the market's expansion is projected to be hampered by the lack of sustainability in synthetic peptide manufacturing. According to a November 2019 paper released by ProteoGenix, the biggest issue in peptide synthesis is the development of sustainable and efficient catalytic techniques.
Inorganic methods such as partnerships between market competitors for peptide synthesis are projected to drive the global peptide synthesis market forward.
GenScript Biotech Corporation, Merck KGaA, ThermoFisher Scientific Inc., Syngene, Lonza, Novo Nordisk A/S, Bachem Holding AG, Gyros Protein Technologies, Creative Diagnostics, CEM Corporation, PuroSynth, AAPPTec, and Biotage AB are among the major companies in the global peptide synthesis industry.